What Ulkar Holding does

Ulkar Holding is a privately held Turkish pharmaceutical conglomerate headquartered in Ümraniye, Istanbul, operating through wholly-owned subsidiaries including Ulkar Kimya (active pharmaceutical ingredient manufacturing), Nobelfarma (finished product contract manufacturing), FARGEM (research and development), and Nobel İlaç (branded-generic marketing and distribution). The group manufactures pharmaceutical APIs across cardiovascular (statins, sartans), anti-ulcerant (prazoles), antihypertensive, NSAID, and antipsychotic therapeutic categories, alongside controlled-release coated micropellets and finished dosage forms (tablets, capsules, suspensions, syrups, creams, ointments, effervescent granules, and cephalosporins), all under cGMP conditions.

The group's production platform comprises three synthesis plants spanning pilot (25-800 L reactors), medium (1,000-2,000 L), and large scale (6,300 L reactors commissioned in 2009, delivering approximately a six-fold capacity increase), together with an 830 m² dedicated micropellet facility operating at approximately 11 tonnes/month using IMA coating machines and GEA fluidized-bed drying technology. R&D is anchored by FARGEM in Düzce, which conducts analytical R&D, synthesis R&D, formulation development, and operates Turkey's only cell culture laboratory in the pharmaceutical industry for Caco-2 and PAMPA permeability testing of oral drug candidates; the group has filed 14 formulation patents and 12 active ingredient synthesis patents, with two granted European patents. NOBEL AFF in Kazakhstan adds 350 million tablets, 150 million capsules, 20 million syrup/suspension, and 10 million cream/pomade annual capacity, and NOBEL Pharmsanoat operates in Uzbekistan.

Revenue is generated through B2B contract manufacturing (fason üretim) of APIs and finished dosage forms for domestic Turkish and international pharmaceutical company clients, alongside proprietary and licensed product sales distributed through Nobel İlaç's field sales network of approximately 1,000 medical representatives and 95 regional managers in Turkey, plus 400+ representatives at international subsidiaries. The group exports to Europe, CIS, Asia, and the Americas, holds regulatory approvals from the Turkish Ministry of Health, BfArM Germany, and EU GMP (obtained 2004), has obtained four USP Verified raw material certifications, and is pursuing FDA certification. Approximately 782 staff are employed across Turkey and international subsidiaries, with about 95% of staff holding university degrees.

Name

Ulkar Holding

Legal name

Ulkar Kimya Sanayii ve Ticaret Anonim Şirketi

Website

https://ulkarkimya.com.tr

Company type

Private

Founded year

1988

Operating status

Operating

Headcount range

1–10 employees

Short description

Ulkar Holding is a Turkish private pharmaceutical conglomerate manufacturing active pharmaceutical ingredients, controlled-release micropellets, and finished dosage forms under cGMP, serving global pharma clients via B2B contract manufacturing and distributing branded generics through Nobel İlaç's 1,400-person sales network.

Ownership category

akta.pro rank

Product category

Pharmaceutical Manufacturing

NAICS

Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (32541), Medicinal and Botanical Manufacturing (325411)

SIC

Pharmaceutical Preparations (2834), Medicinal Chemicals & Botanical Products (2833)

akta.pro primary industry

Small-Molecule API Commercial Manufacturing (HLAGAHAB)

akta.pro secondary industries

Small-Molecule API Process Development & Route Scouting (HLAGAHAA), Small-Molecule CMC Documentation & Regulatory Support (DMF/CMC) (HLAGAHAM), Impurity / Reference Standard Synthesis & Characterization (HLAGAHAG), Drug Product Fill-Finish & Aseptic Manufacturing Services (HLAAAKAB)

Keywords

• Pharmaceutical manufacturing
• Active pharmaceutical ingredients
• Contract manufacturing
• Finished dosage forms
• Controlled-release micropellets

Headquarters

HQ city

İstanbul (Ümraniye)

HQ country

Türkiye

HQ region

Europe

Offices6 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Personnel, Operations, Technology or R&D, Marketing or Sales, Supply Chain, Infrastructure

Revenue model

1. Contract Manufacturing of Pharmaceutical Active Ingredients: Ulkar Kimya manufactures pharmaceutical active ingredients (API) and coated micropellets for domestic and international pharmaceutical companies under contract manufacturing (fason üretim) agreements. Production is cGMP compliant, subject to T.C. Sağlık Bakanlığı and BfArM Germany audits.
2. Contract Manufacturing of Finished Dosage Forms: Nobelfarma operates as a contract manufacturer producing finished pharmaceutical products in various forms (tablet, capsule, suspension, syrup, cream, ointment, effervescent granule, cephalosporin). Products are manufactured to customer-specified formulations and released against finished product specifications.
3. Licensed and Proprietary Pharmaceutical Products: Nobel İlaç markets both in-house developed and manufactured products as well as licensed prescription and OTC products through its extensive sales force across Turkey and international markets.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Ulkar Holding operates an integrated pharmaceutical manufacturing platform. Through Ulkar Kimya, it produces active pharmaceutical ingredients (APIs) and controlled-release coated micropellets under cGMP. Through Nobelfarma, it provides contract manufacturing of finished dosage forms (tablets, capsules, suspensions, syrups, creams, ointments, cephalosporins). Through FARGEM, it conducts formulation, analytical, synthesis, and cell culture R&D. Through Nobel İlaç, it markets proprietary and licensed prescription and OTC products.

Product overview

Ulkar Holding operates as a pharmaceutical conglomerate with three core business divisions: Ulkar Kimya (pharmaceutical active ingredient and micropellet manufacturing), Fargem (pharmaceutical R&D center), and Nobelfarma (contract manufacturing of finished pharmaceutical products), all supporting Nobel İlaç's commercial operations. Ulkar Kimya specializes in synthesis of cardiovascular APIs (statins, sartans), anti-ulcerants (prazoles), and antihypertensives, with three synthesis production facilities and micropellet coating capabilities. Fargem conducts generic drug formulation development, analytical R&D, synthesis R&D, and new drug molecule research with 14 patent applications. Nobelfarma provides full-service contract manufacturing including tablets, capsules, suspensions, syrups, creams, and cephalosporins. The integrated structure enables development from API synthesis through formulation to finished product manufacturing, serving markets across Europe, CIS, Asia, and the Americas.

Differentiator

Problem solved

Functional benefit

Products and services

• Pharmaceutical Active Ingredients (API) Manufacturing Contract manufacturing of pharmaceutical active pharmaceutical ingredients (APIs) including cardiovascular drugs (statins, sartans), anti-ulcerants (prazoles), antihypertensives, NSAIDs, and antipsychotics. Produced at cGMP-compliant facilities in Çerkezköy, Tekirdağ for domestic and international pharmaceutical company clients.
• Controlled-Release Coated Micropellet Manufacturing Contract manufacturing of controlled-release coated micropellets for modified and delayed release pharmaceutical formulations. Production capacity approximately 11 tonnes per month using IMA coating machines and GEA fluidized bed dryer technology. Offered to pharmaceutical company clients.
• Nobelfarma Finished Dosage Form Contract Manufacturing Full-service contract manufacturing of finished pharmaceutical products in forms including tablets, capsules, suspensions, syrups, creams, ointments, effervescent granules, and cephalosporins (tablet, powder, granule, sterile injectable powder). EU GMP certified (since 2004). Products are manufactured to customer-specified formulations and released against finished product specifications.
• Multi-Scale Synthesis Production Services Three distinct synthesis production plants for API manufacturing: pilot/small-scale (four enamel 25–800 L and three stainless steel 160–630 L reactors plus 550 L centrifuge), medium-scale (four enamel 1,000–1,600 L and four stainless steel 1,000–2,000 L reactors plus Halar 1,000 L and two 2,000 L stainless steel centrifuges), and large-scale (6,300 L reactors with Halar and 1,250 L stainless steel centrifuge). Enables transition from R&D through pilot to commercial-scale API production.
• Nobel İlaç Branded Pharmaceutical Products Marketing and distribution of in-house developed and manufactured pharmaceutical products plus licensed prescription and OTC products. Nobel İlaç operates a field sales force of approximately 1,000 medical representatives and 95 regional managers in Turkey, with over 400 international medical representatives at foreign subsidiaries. Therapeutic focus areas include cardiovascular, gastrointestinal, anti-inflammatory, and hypertension.
• FARGEM Pharmaceutical R&D Services Pharmaceutical R&D center offering generic drug formulation development, analytical R&D, synthesis R&D, impurity detection and synthesis, crystal form research, structure elucidation, original drug candidate molecule design and synthesis, and pharmaceutical activity testing. Includes Turkey's only pharmaceutical industry cell culture laboratory. Holds 14 patent applications in pharmaceutical formulation.

Quantifiable outcome

• 6x production capacity increase achieved through 2009 facility expansion
• +2 more outcomes

Named customers8 records

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Four partnerships are on record, tiered core and minor.

• United States Pharmacopeia (USP)coreTechnology or Integration · 8 January 2010Ulkar Kimya joined the USP Drug Raw Material Verification Program, undergoing GMP inspection by USP experts (including a former 28-year FDA veteran), having products tested at USP laboratories, and obtaining USP Verified certifications that support FDA market entry.
• Infa GrupcoreStrategic or Co-development PartnerUlkar Kimya signed a cooperation agreement with Infa Grup (Italy's largest raw material manufacturer) for the production of certain new molecules developed by Infa at Ulkar Kimya facilities, to be sold on the world market. Products manufactured under this agreement will also be developed as finished products within Nobel İlaç for the Turkish market.
• TÜBİTAKminorStrategic or Co-development PartnerFARGEM collaborates with TÜBİTAK (The Scientific and Technological Research Council of Turkey) and national/international universities for research and development projects.
• International UniversitiesminorStrategic or Co-development PartnerFARGEM and Ulkar Holding companies collaborate with national and international universities for scientific R&D projects, knowledge exchange, and talent development.

Scale indicators10 records

Recent moves13 records

Expansion highlights6 records

Regional players

• Abdi İbrahim: Turkey's largest domestic pharmaceutical company with extensive API and finished-product manufacturing — a regional scale peer to Ulkar Holding's combined platform, though broader in therapeutic coverage and brand portfolio.

Direct peers

• Atabay Pharmaceuticals: Turkish pharmaceutical manufacturer producing APIs and finished dosage forms — the closest domestic Turkish peer to Ulkar Kimya in scale and product mix, both serving the domestic generics market and exporting APIs.
• Hovione: Portugal-based global API CDMO offering small-molecule API development, particle engineering, and contract manufacturing — directly comparable to Ulkar Kimya's small-molecule API and process development capabilities for innovator and generic pharma clients.
• Krka: Slovenian generic pharmaceutical company producing APIs and finished formulations with strong CIS and emerging-market presence — directly comparable to Ulkar's generic API portfolio and CIS-focused expansion via Kazakhstan and Uzbekistan.
• Polpharma: Polish pharmaceutical company combining API manufacturing with finished generics across cardiovascular and GI categories — a European mid-market peer to Ulkar with overlapping therapeutic-area focus and contract manufacturing.
• Divi's Laboratories: Indian API manufacturer with large-scale commercial API production and custom synthesis services — directly comparable to Ulkar Kimya's commodity generic APIs (sartans, statins) and multi-kilo commercial manufacturing.
• Carbogen Amcis: Swiss API CDMO specializing in small-molecule synthesis, highly potent APIs, and process development — comparable to Ulkar Kimya's multi-scale synthesis facilities and impurity/reference standard capabilities.
• Cambrex: US/European small-molecule API CDMO providing process R&D, scale-up, and commercial manufacturing under cGMP — closely aligned with Ulkar Kimya's small-molecule API commercial manufacturing and route scouting services.
• Aurobindo Pharma: Indian vertically integrated generic pharmaceutical company with substantial API and finished-dose manufacturing — comparable to Ulkar Holding's combined API (Ulkar Kimya), formulation (Nobelfarma), and distribution (Nobel İlaç) operations.

Broad incumbents

• Sandoz (Novartis): Global generics and biosimilars leader with substantial small-molecule API manufacturing — a broad incumbent whose API business overlaps with Ulkar's generics-and-API strategy across regulated markets.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• YouTubeyoutube.com/channel/UCu4JuJIROuDx6s2u9ZY6wYQ
• Facebookfacebook.com/Nobelilac
• LinkedInlinkedin.com/company/ulkar-holding
• Instagraminstagram.com/nobel_ilac

Compliance7 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Subsidiaries2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ulkar Holding